Models of KPTN-related disorder implicate mTOR signalling in cognitive and overgrowth phenotypes
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain..
KPTN-related disorder is an autosomal recessive disorder associated with germline variants in KPTN (previously known as kaptin), a component of the mTOR regulatory complex KICSTOR. To gain further insights into the pathogenesis of KPTN-related disorder, we analysed mouse knockout and human stem cell KPTN loss-of-function models. Kptn -/- mice display many of the key KPTN-related disorder phenotypes, including brain overgrowth, behavioural abnormalities, and cognitive deficits. By assessment of affected individuals, we have identified widespread cognitive deficits (n = 6) and postnatal onset of brain overgrowth (n = 19). By analysing head size data from their parents (n = 24), we have identified a previously unrecognized KPTN dosage-sensitivity, resulting in increased head circumference in heterozygous carriers of pathogenic KPTN variants. Molecular and structural analysis of Kptn-/- mice revealed pathological changes, including differences in brain size, shape and cell numbers primarily due to abnormal postnatal brain development. Both the mouse and differentiated induced pluripotent stem cell models of the disorder display transcriptional and biochemical evidence for altered mTOR pathway signalling, supporting the role of KPTN in regulating mTORC1. By treatment in our KPTN mouse model, we found that the increased mTOR signalling downstream of KPTN is rapamycin sensitive, highlighting possible therapeutic avenues with currently available mTOR inhibitors. These findings place KPTN-related disorder in the broader group of mTORC1-related disorders affecting brain structure, cognitive function and network integrity.
| Errataetall: |
CommentIn: Brain. 2023 Nov 2;146(11):4399-4400. - PMID 37934918 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:146 |
|---|---|
| Enthalten in: |
Brain : a journal of neurology - 146(2023), 11 vom: 02. Nov., Seite 4766-4783 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.11.2023 Date Revised 10.11.2023 published: Print CommentIn: Brain. 2023 Nov 2;146(11):4399-4400. - PMID 37934918 Citation Status MEDLINE |
|---|
| doi: |
10.1093/brain/awad231 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359380557 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359380557 | ||
| 003 | DE-627 | ||
| 005 | 20231226080740.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/brain/awad231 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359380557 | ||
| 035 | |a (NLM)37437211 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Levitin, Maria O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Models of KPTN-related disorder implicate mTOR signalling in cognitive and overgrowth phenotypes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2023 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Brain. 2023 Nov 2;146(11):4399-4400. - PMID 37934918 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. | ||
| 520 | |a KPTN-related disorder is an autosomal recessive disorder associated with germline variants in KPTN (previously known as kaptin), a component of the mTOR regulatory complex KICSTOR. To gain further insights into the pathogenesis of KPTN-related disorder, we analysed mouse knockout and human stem cell KPTN loss-of-function models. Kptn -/- mice display many of the key KPTN-related disorder phenotypes, including brain overgrowth, behavioural abnormalities, and cognitive deficits. By assessment of affected individuals, we have identified widespread cognitive deficits (n = 6) and postnatal onset of brain overgrowth (n = 19). By analysing head size data from their parents (n = 24), we have identified a previously unrecognized KPTN dosage-sensitivity, resulting in increased head circumference in heterozygous carriers of pathogenic KPTN variants. Molecular and structural analysis of Kptn-/- mice revealed pathological changes, including differences in brain size, shape and cell numbers primarily due to abnormal postnatal brain development. Both the mouse and differentiated induced pluripotent stem cell models of the disorder display transcriptional and biochemical evidence for altered mTOR pathway signalling, supporting the role of KPTN in regulating mTORC1. By treatment in our KPTN mouse model, we found that the increased mTOR signalling downstream of KPTN is rapamycin sensitive, highlighting possible therapeutic avenues with currently available mTOR inhibitors. These findings place KPTN-related disorder in the broader group of mTORC1-related disorders affecting brain structure, cognitive function and network integrity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a animal model | |
| 650 | 4 | |a iPSC | |
| 650 | 4 | |a mTOR | |
| 650 | 4 | |a macrocephaly | |
| 650 | 4 | |a neurodevelopmental disorders | |
| 650 | 4 | |a recessive | |
| 650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Mechanistic Target of Rapamycin Complex 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a KPTN protein, human |2 NLM | |
| 650 | 7 | |a Microfilament Proteins |2 NLM | |
| 700 | 1 | |a Rawlins, Lettie E |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez-Andrade, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Arshad, Osama A |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Stephan C |e verfasserin |4 aut | |
| 700 | 1 | |a Sawiak, Stephen J |e verfasserin |4 aut | |
| 700 | 1 | |a Iffland, Phillip H |c 2nd |e verfasserin |4 aut | |
| 700 | 1 | |a Andersson, Malin H L |e verfasserin |4 aut | |
| 700 | 1 | |a Bupp, Caleb |e verfasserin |4 aut | |
| 700 | 1 | |a Cambridge, Emma L |e verfasserin |4 aut | |
| 700 | 1 | |a Coomber, Eve L |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Herkert, Johanna C |e verfasserin |4 aut | |
| 700 | 1 | |a Ironfield, Holly |e verfasserin |4 aut | |
| 700 | 1 | |a Jory, Logan |e verfasserin |4 aut | |
| 700 | 1 | |a Kretz, Perrine F |e verfasserin |4 aut | |
| 700 | 1 | |a Kant, Sarina G |e verfasserin |4 aut | |
| 700 | 1 | |a Neaverson, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Nibbeling, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Rowley, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Relton, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Sanderson, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Ethan M |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Shuen, Andrew Y |e verfasserin |4 aut | |
| 700 | 1 | |a Schreiber, John |e verfasserin |4 aut | |
| 700 | 1 | |a Tuck, Liz |e verfasserin |4 aut | |
| 700 | 1 | |a Tonks, James |e verfasserin |4 aut | |
| 700 | 1 | |a Terkelsen, Thorkild |e verfasserin |4 aut | |
| 700 | 1 | |a van Ravenswaaij-Arts, Conny |e verfasserin |4 aut | |
| 700 | 1 | |a Vasudevan, Pradeep |e verfasserin |4 aut | |
| 700 | 1 | |a Wenger, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Day, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Hunter, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Minal |e verfasserin |4 aut | |
| 700 | 1 | |a Lelliott, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Crino, Peter B |e verfasserin |4 aut | |
| 700 | 1 | |a Yalcin, Binnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Crosby, Andrew H |e verfasserin |4 aut | |
| 700 | 1 | |a Baple, Emma L |e verfasserin |4 aut | |
| 700 | 1 | |a Logan, Darren W |e verfasserin |4 aut | |
| 700 | 1 | |a Hurles, Matthew E |e verfasserin |4 aut | |
| 700 | 1 | |a Gerety, Sebastian S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain : a journal of neurology |d 1945 |g 146(2023), 11 vom: 02. Nov., Seite 4766-4783 |w (DE-627)NLM000126292 |x 1460-2156 |7 nnns |
| 773 | 1 | 8 | |g volume:146 |g year:2023 |g number:11 |g day:02 |g month:11 |g pages:4766-4783 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/brain/awad231 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 146 |j 2023 |e 11 |b 02 |c 11 |h 4766-4783 | ||